STOCK TITAN
  1. Home
  2. News
  3. AZN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

Rhea-AI Summary
AstraZeneca's TRUQAP (capivasertib) Approved in the US for HR-positive, HER2-negative breast cancer with specific biomarker alterations, showing a 50% reduction in the risk of disease progression or death. The approval is based on the CAPItello-291 Phase III trial results, offering a new treatment option for patients with these specific biomarkers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
News

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

Rhea-AI Summary
AstraZeneca: Positive results from the EMERALD-1 Phase III trial show that IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated significant improvement in progression-free survival versus TACE alone in patients with hepatocellular carcinoma. The trial continues to follow the secondary endpoint of overall survival. The safety profiles for IMFINZI and TACE plus bevacizumab were consistent with the known profile of each medicine, and there were no new safety findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
clinical trial
-
News

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

Rhea-AI Summary
AstraZeneca (AZN) aims to significantly increase US renewable natural gas (RNG) productivity through an expanded collaboration with Vanguard Renewables. The partnership seeks to accelerate parity with fossil fuel-generated natural gas by leveraging AstraZeneca's global industrial-scale manufacturing and digital capabilities. The collaboration plans to increase RNG yield and generate a step change improvement in production, aiming to enhance access and cost-effectiveness of RNG. The announcement builds on a prior sector-first collaboration and contributes to AstraZeneca's Ambition Zero Carbon strategy for value chain decarbonization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News

Compugen Reports Third Quarter 2023 Results

Rhea-AI Summary
Compugen Ltd. announced the progress of rilvegostomig, AstraZeneca's PD-1/TIGIT bi-specific derived from Compugen's COM902, into Phase 3 as adjuvant therapy for biliary tract cancer. Enrollment was completed in a proof-of-concept study for metastatic colorectal cancer. The company presented new clinical data at SITC 2023, reinforcing the anti-tumor activity of COM701 and initial data suggesting PVRL2 as a potential biomarker. Pre-clinical data also highlighted the potential of COM503's antibody approach to treat cancer. Financial results showed cash, cash equivalents, and cash investments of approximately $57.5 million as of September 30, 2023, expected to fund operations through the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
earnings
-
News

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial

Rhea-AI Summary
AstraZeneca announces positive results from the Phase IIb ZENITH-CKD trial, showing significant reductions in urinary albumin-to-creatinine ratio (UACR) with the combination of zibotentan and dapagliflozin compared to dapagliflozin alone. The high-dose combination resulted in a 52.5% reduction, while the low-dose combination showed a 47.7% reduction. The trial also demonstrated acceptable tolerability with low rates of fluid retention. Plans for Phase III are underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
clinical trial
-
News

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)

Rhea-AI Summary
AstraZeneca's Supplemental Biologics License Application for a self-administered flu vaccine has been accepted for review by the FDA. If approved, FLUMIST QUADRIVALENT will be the first flu vaccine that can be self-administered or administered by caregivers. The FDA's decision is expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
News

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Rhea-AI Summary
Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
-
News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU shows positive results in the primary analysis of the DESTINY-PanTumor02 Phase II trial, demonstrating clinically meaningful responses and a survival benefit in previously treated patients with HER2-expressing solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
-
News

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Rhea-AI Summary
Positive results from the pivotal TROPION-Lung01 phase 3 trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
News

Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan shows positive results in Phase III trial for breast cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $67.01 as of January 10, 2025.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 207.8B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.
Stock AZN logo
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

#40 Ranked by Market Cap
#1616 Ranked by Dividends

AZN Stock Data

207.80B
3.10B
0.01%
16.77%
0.32%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge